A deletion and point mutation study of the human papillomavirus type 16 major capsid gene

Virus Research

Volumn 122, Issue 1-2, 2006, Pages 154-163

  Varsani, Arvind ^a   Williamson, Anna Lise ^b,c   Jaffer, Mohamed A ^a   Rybicki, Edward P ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antigenicity; Deletion; HPV 16; L1; Papillomavirus; VLP

Indexed keywords

CAPSID PROTEIN; MAJOR CAPSID PROTEIN L1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H16:9A; MONOCLONAL ANTIBODY H16:D9; MONOCLONAL ANTIBODY H16:E70; MONOCLONAL ANTIBODY H16:I23; MONOCLONAL ANTIBODY H16:J4; MONOCLONAL ANTIBODY H16:U4; MONOCLONAL ANTIBODY H16:V5; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGENICITY; ARTICLE; BACULOVIRUS; CARBOXY TERMINAL SEQUENCE; CONFORMATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENE DELETION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN PAPILLOMAVIRUS TYPE 16; INSECT CELL; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; VIRUS PARTICLE; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CELL LINE; EPITOPES; HUMAN PAPILLOMAVIRUS 16; MICROSCOPY, ELECTRON, TRANSMISSION; POINT MUTATION; SEQUENCE DELETION; SPODOPTERA; VIRUS ASSEMBLY;

ESCHERICHIA COLI; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; INSECTA; MIRIDAE; PAPILLOMAVIRIDAE;

EID: 33750319866     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2006.07.012     Document Type: Article

References (46)

1. Bachmann M.F., and Zinkernagel R.M. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today 17 (1996) 553-558
2. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin D.D., Orth G., Schiller J.T., and Lowy D.R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69 (1995) 3959-3963
3. Carter J.J., Wipf G.C., Benki S.F., Christensen N.D., and Galloway D.A. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J. Virol. 77 (2003) 11625-11632
4. Chan S.Y., Bernard H.U., Ong C.K., Chan S.P., Hofmann B., and Delius H. Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses. J. Virol. 66 (1992) 5714-5725
5. Chen X.S., Garcea R.L., Goldberg I., Casini G., and Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell. 5 (2000) 557-567
6. Chen X.S., Casini G., Harrison S.C., and Garcea R.L. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J. Mol. Biol. 307 (2001) 173-182
7. Chen Y., Ghim S.J., Jenson A.B., and Schlegel R. Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes. J. Gen. Virol. 79 (1998) 2137-2146
8. Christensen N.D., and Kreider J.W. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J. Virol. 64 (1990) 3151-3156
9. Christensen N.D., Kirnbauer R., Schiller J.T., Ghim S.J., Schlegel R., Jenson A.B., and Kreider J.W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205 (1994) 329-335
10. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., Cladel N.M., and Galloway D.A. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 (1996) 174-184
11. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., McClements W.L., Ludmerer S.W., and Jansen K.U. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291 (2001) 324-334
12. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89 (2003) 101-105
13. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J. Virol. 76 (2002) 6480-6486
14. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and Zur Hausen H. Classification of papillomaviruses. Virology 20 (2004) 17-27
15. Fligge C., Giroglou T., Streeck R.E., and Sapp M. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology 283 (2001) 353-357
16. Greenstone H.L., Nieland J.D., de Visser K.E., De Bruijn M.L., Kirnbauer R., Roden R.B., Lowy D.R., Kast W.M., and Schiller J.T. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 1800-1805
17. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
18. Ho L., Chan S.Y., Chow V., Chong T., Tay S.K., Villa L.L., and Bernard H.U. Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J. Clin. Microbiol. 29 (1991) 1765-1772
19. IARC, 1999. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. Geneva, 16-18 February 1999, http://www.who.int/vaccines-documents/DocsPDF99/www9914.pdf.
20. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., Martinez D., Ellis R.W., and Shaw A.R. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13 (1995) 1509-1514
21. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
22. Li M., Cripe T.P., Estes P.A., Lyon M.K., Rose R., and Garcea R.L. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J. Virol. 71 (1997) 2988-2995
23. Li M., Beck D.L., Estes P.A., Lyon M.K., and Garcea R.L. Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J. Virol. 72 (1998) 2160-2167
24. Liu W.J., Liu X.S., Zhao K.N., Leggatt G.R., and Frazer I.H. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 273 (2000) 374-382 (in process citation)
25. Liu X.S., Liu W.J., Zhao K.N., Liu Y.H., Leggatt G., and Frazer I.H. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol. Cell. Biol. 80 (2002) 21-29
26. McCarthy M.P., White W.I., Palmer-Hill F., Koenig S., and Suzich J.A. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J. Virol. 72 (1998) 32-41
27. Muller M., Zhou J., Reed T.D., Rittmuller C., Burger A., Gabelsberger J., Braspenning J., and Gissmann L. Chimeric papillomavirus-like particles. Virology 234 (1997) 93-111
28. Nieland J.D., Da Silva D.M., Velders M.P., de Visser K.E., Schiller J.T., Muller M., and Kast W.M. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J. Cell. Biochem. 73 (1999) 145-152
29. Pastrana D.V., Vass W.C., Lowy D.R., and Schiller J.T. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 279 (2001) 361-369
30. Roden R.B., Weissinger E.M., Henderson D.W., Booy F., Kirnbauer R., Mushinski J.F., Lowy D.R., and Schiller J.T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68 (1994) 7570-7574
31. Roden R.B., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., Schiller J.T., and Kirnbauer R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol. 71 (1997) 6247-6252
32. Sapp M., Fligge C., Petzak I., Harris R., and Streeck R.E. Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly concerned cysteines. J. Virol. 72 (1998) 6186-6189
33. Sandalon Z., and Oppenheim A. Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 237 (10-27-1997) 414-421
34. Seedorf K., Krammer G., Durst M., Suhai S., and Rowekamp W.G. Human papillomavirus type 16 DNA sequence. Virology 145 (1985) 181-185
35. Slupetzky K., Shafti-Keramat S., Lenz P., Brandt S., Grassauer A., Sara M., and Kirnbauer R. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J. Gen. Virol. 82 (2001) 2799-2804
36. Steller M. Cervical cancer vaccines: progress and prospects. J. Soc. Gynecol. Investig. 9 (2002) 254
37. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., and Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11553-11557
38. Touze A., El Mehdaoui S., Sizaret P.Y., Mougin C., Munoz N., and Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J. Clin. Microbiol. 36 (1998) 2046-2051
39. Varsani A., Williamson A.L., Rose R.C., Jaffer M., and Rybicki E.P. Expression of human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Archiv. Virol. 148 (2003) 1771-1786
40. Varsani A., Williamson A.L., de Villiers D., Becker I., Christensen N.D., and Rybicki E.P. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J. Virol. 77 (2003) 8386-8393
41. Varsani A., Williamson A.L., Stewart D., and Rybicki E.P. Transient expression of human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res. 120 (2006) 91-96
42. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
43. Wang Z., Christensen N., Schiller J.T., and Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J. Gen. Virol. 78 (1997) 2209-2215
44. White W.I., Wilson S.D., Palmer-Hill F.J., et al. Characterization of major neutralizing epitope on human papillomavirus type 16 L1. J. Virol. 73 (1999) 4882-4889
45. Yamada T., Wheeler C.M., Halpern A.L., Stewart A.C., Hildesheim A., and Jenison S.A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J. Virol. 69 (1995) 7743-7753
46. Zhou J., Doorbar J., Sun X.Y., Crawford L.V., McLean C.S., and Frazer I.H. Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein. Virology 185 (1991) 625-632